Rhenman & Partners Asset Management Ab Mirati Therapeutics, Inc. Transaction History

Rhenman & Partners Asset Management Ab

$1.2 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$27.8 - $45.35 $4.87 Million - $7.94 Million	175,000 New	175,000 $7.62 Million
Q2 2023 Aug 11, 2023	SELL	$36.13 - $49.49 $2.71 Million - $3.71 Million	-75,000 Reduced 34.88%	140,000 $5.06 Million
Q1 2023 May 11, 2023	SELL	$36.54 - $54.26 $3.11 Million - $4.61 Million	-85,000 Reduced 28.33%	215,000 $7.99 Million
Q4 2022 Feb 13, 2023	BUY	$41.27 - $98.62 $4.25 Million - $10.2 Million	102,933 Added 52.23%	300,000 $13.6 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $420,486 - $612,708	7,067 Added 3.72%	197,067 $13.3 Million
Q2 2022 Aug 12, 2022	BUY	$39.16 - $88.71 $1.57 Million - $3.57 Million	40,200 Added 26.84%	190,000 $12.8 Million
Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $15,163 - $30,194	-200 Reduced 0.13%	149,800 $12.3 Million
Q3 2021 Nov 12, 2021	SELL	$132.13 - $177.45 $1.98 Million - $2.66 Million	-15,000 Reduced 9.09%	150,000 $26.5 Million
Q2 2021 Aug 13, 2021	BUY	$144.0 - $179.73 $2.16 Million - $2.7 Million	15,000 Added 10.0%	165,000 $26.7 Million
Q1 2021 May 14, 2021	BUY	$158.92 - $221.61 $7.95 Million - $11.1 Million	50,000 Added 50.0%	150,000 $25.7 Million
Q4 2020 Jan 19, 2021	SELL	$162.05 - $240.27 $2.32 Million - $3.44 Million	-14,311 Reduced 12.52%	100,000 $22 Million
Q3 2020 Oct 13, 2020	BUY	$113.26 - $167.27 $1.62 Million - $2.39 Million	14,311 Added 14.31%	114,311 $19 Million
Q2 2020 Jul 16, 2020	SELL	$72.01 - $120.39 $2.16 Million - $3.61 Million	-30,000 Reduced 23.08%	100,000 $11.4 Million
Q1 2020 Apr 16, 2020	BUY	$69.78 - $116.21 $348,900 - $581,050	5,000 Added 4.0%	130,000 $9.99 Million
Q4 2019 Jan 17, 2020	BUY	$70.76 - $128.86 $1.77 Million - $3.22 Million	25,000 Added 25.0%	125,000 $16.1 Million
Q3 2019 Oct 16, 2019	SELL	$77.91 - $109.6 $6.39 Million - $8.99 Million	-82,008 Reduced 45.06%	100,000 $7.79 Million
Q2 2019 Jul 22, 2019	BUY	$59.49 - $104.71 $3.27 Million - $5.75 Million	54,915 Added 43.21%	182,008 $18.7 Million
Q1 2019 Apr 11, 2019	BUY	$43.65 - $78.95 $1.84 Million - $3.32 Million	42,093 Added 49.52%	127,093 $9.32 Million
Q4 2018 Feb 05, 2019	BUY	$32.0 - $47.43 $2.72 Million - $4.03 Million	85,000 New	85,000 $3.61 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account